Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2014

View Archived Issues

Eli Lilly and Immunocore to discover and develop novel cancer therapies

TTP-054 demonstrates the ability to lower HbA1c in patients with type 2 diabetes

Chase Pharmaceuticals to begin phase II study of CPC-201

Researchers present novel ASOs as potential therapies for tauopathies

Virobay completes series B financing round

Enrollment completed in study of protein-based biomarker blood test for breast cancer

Novel agents for tuberculosis patented by Janssen R&D Ireland

Galapagos designs new GPR84 agonists

Cellerant Therapeutics divulges new anti-IL1RAP MAbs

AVEO Pharmaceuticals presents new anti-GDF-15 MAbs

Researchers at Rockefeller University patent new modified anti-CD4 MAbs

Significant benefits seen with DA-1229 in diabetes trial

New anti-Notch 3 antibodies selected by AVEO Pharmaceuticals

French group patents new spiroisoxazoline derivatives

Phase III trial of biosimilar of etanercept begins in chronic plaque psoriasis

Capricor Therapeutics reports results from phase I portion of the ALLSTAR trial

Isis Pharmaceuticals begins phase II study of ISIS-APO(a)Rx in patients with high Lp(a)

ImQuest Pharmaceuticals receives FDA approval to initiate trials of IQP-0528 gel

Resolve Therapeutics begins phase II study of RSLV-132 in SLE

OncoMed Pharmaceuticals begins phase II ALPINE trial of tarextumab

Phase III study of trametinib and dabrafenib in melanoma stopped early due to benefit

FDA grants breakthrough therapy designation to pirfenidone for IPF

Cynapsus begins phase II studies of APL-130277 in Parkinson's disease

Ruthigen treats first subjects in trial of RUT-58-60

Seres Health completes enrollment in study of SER-109

Researchers develop low-cost, rapid, point-of-care test for the detection of M. tuberculosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...